Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Underterskel SCS eller BMT (TRADITION)

16. november 2026 oppdatert av: Moens Maarten

Den holistiske responsen til pasienter med vedvarende ryggmargsmertesyndrom type II ved subterskel ryggmargsstimulering sammenlignet med beste medisinske behandling, undersøkt av en multisentrisk randomisert kontrollert studie

Given the substantial socioeconomic impact of Spinal Cord Stimulation (SCS) implantations and given that currently no direct high-quality evidence with a relevant outcome measurement is available to guide the treatment choice between subthreshold SCS versus best medical treatment in patients with Persistent Spinal Pain Syndrome Type 2 (PSPS-T2), we here propose a scientifically well-constructed randomized controlled trial to answer this question.

The primary scientific objective is to examine whether subthreshold SCS, compared to best medical treatment, provided to patients with PSPS-T2 results in a higher percentage of clinical holistic responders at 6 months. The secondary objective of the study is to examine if subthreshold SCS compared with BMT is having more efficacy in improving patients' individual competencies for self-management, increasing the likelihood to return to work, work status and healthcare expenditure, improving pain relief, obtaining pain medication reduction, decreasing anxiety and depression, increasing quality of life and decreasing disability.

Studieoversikt

Detaljert beskrivelse

After filling in the questionnaires at the 6 months follow-up visit, patients could change treatment groups (in both directions). This decision will be a shared decisions between patient and treating physician in case the randomized intervention did not provided enough pain relief.

Studietype

Intervensjonell

Registrering (Antatt)

114

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Jette, Belgia, 1090
        • Universitair Ziekenhuis Brussel
      • Mechelen, Belgia
        • Emmaüs, AZ Sint-Maarten
      • Roeselare, Belgia
        • AZ Delta
      • Turnhout, Belgia
        • AZ Turnhout

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Persistent Spinal Pain Syndrome Type II (PSPS-T2)
  • Chronic pain as a result of PSPS-T2 that exists for at least 6 months with a pain intensity of at least 4/10 on the Numeric Rating Scale, refractory to conservative treatment.
  • PSPS-T2 patients eligible for subthreshold SCS
  • Age > 18 years
  • Patient has been informed of the study procedures and has given written informed consent
  • Patient willing to comply with study protocol including attending the study visits

Exclusion Criteria:

  • Expected inability of patients to receive or properly operate the spinal cord stimulation system
  • Evidence of an active psychiatric disorder
  • Suffering from another chronic illness characterised by chronic generalized widespread pain (e.g. rheumatoid arthritis, fibromyalgia, chronic fatigue syndrome, scleroderma).
  • Pregnancy

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Beste medisinske behandling

For each patient who is randomized to BMT, an optimal individual treatment plan will be developed by the treating physician.

Aktiv komparator: Underterskel ryggmargsstimulering

SCS will be programmed at subthreshold stimulation.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Clinical holistic responder status
Tidsramme: The change between the baseline screening and the evaluation at 1 month, 6 months and 12 months.

The clinical holistic responder status as a composite measure represents the global effect of a treatment, based on a combination of questionnaires.

The change between the baseline screening and the evaluation at 1 month, 6 months and 12 months.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall pain intensity with Visual Analogue Scale (VAS)
Tidsramme: The change between the baseline screening and the evaluation at 1 month, 6 months and 12 months.

Overall pain, defined as a combination of back and leg pain, but not pain from other body parts, measured with the VAS (100mm)

The change between the baseline screening and the evaluation at 1 month, 6 months and 12 months.
Pain medication use
Tidsramme: The change between the baseline screening and the evaluation at 1 month, 6 months and 12 months.

Open question regarding the dosage, frequency and type of pain medication

The change between the baseline screening and the evaluation at 1 month, 6 months and 12 months.
Functional disability
Tidsramme: The change between the baseline screening and the evaluation at 1 month, 6 months and 12 months.

The functional disabilities will be assessed with the Oswestry Disability Index (ODI)

The change between the baseline screening and the evaluation at 1 month, 6 months and 12 months.
Health related quality of life
Tidsramme: The change between the baseline screening and the evaluation at 1 month, 6 months and 12 months.

Health related quality of life, evaluated with the EuroQol with five dimensions and 5 levels

The change between the baseline screening and the evaluation at 1 month, 6 months and 12 months.
Patient global impression of change
Tidsramme: Evaluated at 1 month, 6 months and 12 months.

Patients will be asked to quantify the impression of change after treatment using the Patient Global Impression of Change scale (PGIC).

Evaluated at 1 month, 6 months and 12 months.
Work status
Tidsramme: The change between the baseline screening and the evaluation at 1 month, 6 months and 12 months.

Work status is evaluated with a self-designed questionnaire

The change between the baseline screening and the evaluation at 1 month, 6 months and 12 months.
Patients' individual competencies for self-management
Tidsramme: The change between the baseline screening and the evaluation at 1 month, 6 months and 12 months.

Patient activation measure-13 (PAM) is a 13-item instrument which assesses self-reported behaviour, knowledge, and confidence for self-management of one's health.

The change between the baseline screening and the evaluation at 1 month, 6 months and 12 months.
Healthcare utilisation.
Tidsramme: The change between the baseline screening and the evaluation at 1 month, 6 months and 12 months.

Healthcare expenditure will be investigated by self-reporting methods.

The change between the baseline screening and the evaluation at 1 month, 6 months and 12 months.
Anxiety and Depression.
Tidsramme: The change between the baseline screening and the evaluation at 1 month, 6 months and 12 months.

The hospital Anxiety and Depression Scale (HADS) will measure symptoms of anxiety and depression

The change between the baseline screening and the evaluation at 1 month, 6 months and 12 months.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

7. februar 2022

Primær fullføring (Antatt)

1. desember 2026

Studiet fullført (Antatt)

1. desember 2026

Datoer for studieregistrering

Først innsendt

29. november 2021

Først innsendt som oppfylte QC-kriteriene

22. desember 2021

Først lagt ut (Faktiske)

23. desember 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere